The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) + ipilimumab (ipi).
 
Kabir Grewal
No Relationships to Disclose
 
Pankaj Chauhan
No Relationships to Disclose
 
Sagar Mukhida
No Relationships to Disclose
 
Nizar Tannir
Stock and Other Ownership Interests - Amgen; BioCryst; Johnson & Johnson/Janssen; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Nektar; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Neha Venkatesh
No Relationships to Disclose
 
Amishi Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Amado Zurita
Honoraria - Amedco; CancerNet; Janssen; McKesson
Consulting or Advisory Role - Bayer; Exelixis; Foundation Medicine; Hikma Pharmaceuticals; Pfizer
Research Funding - Advanced Biochemical Compounds; Astellas Pharma; Clarity Pharmaceuticals; Curium Pharma; Merck; Pfizer
Travel, Accommodations, Expenses - Hikma Pharmaceuticals; Janssen Oncology
 
Andrew Johns
No Relationships to Disclose
 
Matthew Campbell
Honoraria - Axdev; Curio Science; Eisai; Exelixis; MJH Life Sciences; Seagen; Targeted Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; Exelixis; SeaGen
 
Sangeeta Goswami
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Eric Jonasch
Consulting or Advisory Role - Aveo; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Merck; NiKang Therapeutics; Novartis; Takeda; Telix Pharmaceuticals
Research Funding - Abbvie (Inst); Arrowhead Pharmaceuticals (Inst); Aveo (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); NiKang Therapeutics (Inst); ProfoundBio (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Jennifer McQuade
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Omar Alhalabi
Consulting or Advisory Role - Adaptimmune; Bicycle Therapeutics; Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst)
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Andrew Hahn
Honoraria - Binacea; Kaplan Partners in Knowledge; Medscape
Consulting or Advisory Role - AVEO; Eisai; Exelixis; Intellisphere; Janssen Scientific Affairs; Pfizer
Research Funding - Bayer; Eisai (Inst)
Travel, Accommodations, Expenses - Dava Oncology